Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

SARS-CoV-2 Nucleocapsid anticorps

SARS-CoV-2 N Reactivité: SARS Coronavirus-2 (SARS-CoV-2) ELISA, WB, IF Hôte: Souris Monoclonal 3851 unconjugated
N° du produit ABIN6952432
  • Antigène Voir toutes SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) Anticorps
    SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)
    Reactivité
    • 80
    • 13
    • 5
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    SARS Coronavirus-2 (SARS-CoV-2)
    Hôte
    • 34
    • 26
    • 21
    • 4
    • 1
    • 1
    Souris
    Clonalité
    • 68
    • 13
    • 5
    Monoclonal
    Conjugué
    • 67
    • 11
    • 5
    • 2
    • 1
    Cet anticorp SARS-CoV-2 Nucleocapsid est non-conjugé
    Application
    • 71
    • 35
    • 10
    • 10
    • 6
    • 5
    • 4
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    ELISA, Western Blotting (WB), Immunofluorescence (IF)
    Specificité
    Specific for the nucleoprotein of the SARS virus.
    Purification
    SARS-CoV-2 (COVID-19, 2019-nCoV) Nucleoprotein antibody is purified from ascites fluid or culture medium by protein A chromoatography or sequential differential precipitations.
    Clone
    3851
    Isotype
    IgG2b
    Top Product
    Discover our top product SARS-CoV-2 N Anticorps primaire
  • Indications d'application
    Optimal working dilution should be determined by the investigator.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    phosphate saline buffer (0.01M, pH 7.2) containing 0.1 % sodium azide preservative. No stabilizing proteins have been added.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    -20 °C
    Stockage commentaire
    antibody can be stored at -20°C, stable for one year.
    Date de péremption
    12 months
  • Qiao, Wotring, Zhang, Jiang, Xiao, Watt, Gattis, Scandalis, Freier, Zheng, Pretto, Ellison, Swayze, Guo, Sexton, Chinnaiyan: "Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection." dans: PloS one, Vol. 18, Issue 2, pp. e0281281, (2023) (PubMed).

    Qiao, Wotring, Zheng, Zhang, Zhang, Jiang, Pretto, Eyunni, Parolia, He, Cheng, Cao, Wang, Su, Ellison, Wang, Qin, Yan, Zhou, Ma, Sexton, Chinnaiyan: "Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, Issue 30, pp. e2221809120, (2023) (PubMed).

    Wotring, Fursmidt, Ward, Sexton: "Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern." dans: Journal of dairy science, (2022) (PubMed).

    Sherman, Mirabelli, Tang, Khan, Leix, Kennedy, Graham, Willer, Tai, Sexton, Wobus, Emmer: "Identification of cell type specific ACE2 modifiers by CRISPR screening." dans: PLoS pathogens, Vol. 18, Issue 3, pp. e1010377, (2022) (PubMed).

    Mirabelli, Sherman, Wotring, El Saghir, Bragazzi Cunha, Harder, Sexton, Emmer, Wobus: "ARF6 is an important host factor for SARS-CoV-2 infection in vitro." dans: bioRxiv : the preprint server for biology, (2022) (PubMed).

    Wotring, McCarty, Shafiq, Zhang, Nguyen, Meyer, Fursmidt, Mirabelli, Clasby, Wobus, OMeara, Sexton: "In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment." dans: bioRxiv : the preprint server for biology, (2022) (PubMed).

    Yao, Subedi, Liu, Khalasawi, Pretto-Kernahan, Wotring, Wang, Yin, Jiang, Fu, Dimitrion, Li, Veenstra, Yi, McKinnon, McKinnon, Sexton, Zhou, Mi: "Surface translocation of ACE2 and TMPRSS2 upon TLR4/7/8 activation is required for SARS-CoV-2 infection in circulating monocytes." dans: Cell discovery, Vol. 8, Issue 1, pp. 89, (2022) (PubMed).

    Wotring, McCarty, Shafiq, Zhang, Nguyen, Meyer, Fursmidt, Mirabelli, Clasby, Wobus, OMeara, Sexton: "In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment." dans: Vaccines, Vol. 10, Issue 8, (2022) (PubMed).

    Mirabelli, Wotring, Zhang, McCarty, Fursmidt, Pretto, Qiao, Zhang, Frum, Kadambi, Amin, OMeara, Spence, Huang, Alysandratos, Kotton, Handelman, Wobus, Weatherwax, Mashour, OMeara, Chinnaiyan, Sexton: "Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Issue 36, (2021) (PubMed).

    Baang, Smith, Mirabelli, Valesano, Manthei, Bachman, Wobus, Adams, Washer, Martin, Lauring: "Prolonged SARS-CoV-2 replication in an immunocompromised patient." dans: The Journal of infectious diseases, (2020) (PubMed).

    Mirabelli, Wotring, Zhang, McCarty, Fursmidt, Frum, Kadambi, Amin, OMeara, Pretto, Spence, Huang, Alysandratos, Kotton, Handelman, Wobus, Weatherwax, Mashour, OMeara, Sexton: "Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19." dans: bioRxiv : the preprint server for biology, (2020) (PubMed).

  • Antigène
    SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)
    Autre désignation
    SARS-CoV-2 Nucleocapsid Protein (SARS-CoV-2 N Produits)
    Synonymes
    anticorps nucleocapsid phosphoprotein, anticorps N
    Classe de substances
    Viral Protein
Vous êtes ici:
Support technique